Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.

Zacks Equity Research

GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

by Zacks Equity Research

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.

Zacks Equity Research

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Moderna (MRNA) concluded the recent trading session at $58.39, signifying a -0.56% move from its prior day's close.

Zacks Equity Research

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty

by Zacks Equity Research

Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.

Zacks Equity Research

MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine

by Zacks Equity Research

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.

Zacks Equity Research

Company News for Oct 1, 2024

by Zacks Equity Research

Companies In The Article Are:NIO, MRNA, AMC,FUTU

Zacks Equity Research

Moderna (MRNA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $66.83, moving +1.64% from the previous trading session.

Zacks Equity Research

Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Moderna (MRNA) reachead $63.94 at the closing of the latest trading day, reflecting a -0.31% change compared to its last close.

Zacks Equity Research

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

by Zacks Equity Research

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.